CurrentKaiser PermanentePolicy N/A

Meniett positive pressure pulse therapy for Ménière's disease — Coverage Criteria

This policy governs medical necessity and utilization management for use of the Meniett positive pressure pulse generator (transtympanic micropressure therapy) for patients with Ménière's disease within the Georgia region of Kaiser Permanente.

Policy Summary

PayerKaiser Permanente

PolicyMeniett positive pressure pulse therapy for Ménière's disease — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateDec 12, 2008

Next Review DateN/A

Key ActionObtain prior authorization with indicators E2120/A4638 and provide a letter of necessity documenting severe Ménière's disease after failed standard therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Recommendation againstPolicy stance on Meniett

H81.09Diagnosis code listed

E2120, A4638CPT/HCPCS indicators

Failed standard therapyIndication requirement

Otitis ~13.5%Common adverse event

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Meniett Positive Pressure Therapy

Covered with criteria

Covered when ALL of the following are met:

Primary coverage criteria: Patient has a diagnosis of severe Ménière's disease (ICD-10 H81.09)

Document diagnosis code H81.09

Primary coverage criteria: Patient has had no significant improvement with standard/conservative therapy (for example: low‑sodium diet, diuretics, stress management)

Must document prior adequate trials of conservative therapies

Primary coverage criteria: A letter of medical necessity from the treating ENT physician is provided

Letter must document severity, prior therapies tried, and rationale for device

Contraindications / Exclusionary considerations: Inadequate trial of standard therapy

Presence of this excludes coverage until adequate trial completed

Contraindications / Exclusionary considerations: Use is considered experimental/investigational (policy generally recommends against positive pressure therapy but allows rare exceptions)

Policy states recommendation against routine prescribing; rare individual exceptions may be considered

Policy stance: Positive pressure pulse therapy (Meniett) is generally not recommended for treatment of Ménière's disease. Coverage is limited to very specific, rare circumstances only when the member has severe Ménière's disease (H81.09), has had no significant improvement with standard/conservative therapy (for example, low-sodium diet, diuretics, stress management), and a letter of medical necessity from the treating ENT physician is provided. The policy further notes that use may be considered experimental or investigational in many cases and may be denied when an adequate trial of standard therapy has not occurred.

Evidence summary and recommendation: A systematic review and two small randomized controlled trials found no clear benefit of Meniett-style positive pressure devices for Ménière's disease; the guideline statement therefore issues a recommendation against prescribing positive pressure therapy. Aggregate evidence quality is reported as Grade B with a high level of confidence in the conclusion that there is no net benefit. External coverage guidance (Aetna) similarly considers the Meniett device experimental and investigational because effectiveness has not been established.

Diagnosis and Procedure Coding

Indicators / CPT/HCPCSHCPCS

E2120	Indicator listed in policy (documented as 'Indicators: E2120')
A4638	Indicator listed in policy (documented as 'Indicators: A4638')

Diagnosis (ICD-10)ICD-10

H81.09

Ménière's disease

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Meniett (positive pressure therapy) prior to initiation of treatment. Submit a prior authorization request with clinical documentation demonstrating that all conservative therapy prerequisites have been met and that the treating ENT supports the request.

Affected codes: E2120, A4638
Effective date: 2008-12-12

Documentation Required

Physician Documentation Required

A signed letter of medical necessity from the treating otolaryngologist (ENT) must accompany the prior authorization submission. The letter should describe the diagnosis (Ménière's disease), symptom severity, prior treatments tried, response to those treatments, rationale for considering Meniett therapy, and anticipated treatment plan and duration.

Include documentation of ENT evaluation and recommendation
Specify dates and outcomes of prior therapies

Clinical Background

Ménière's disease is an inner ear disorder characterized by episodic spontaneous vertigo, tinnitus, aural fullness, and fluctuating sensorineural hearing loss attributed to presumed endolymphatic hydrops. Conventional management emphasizes conservative measures such as a low-sodium diet, diuretics, and stress reduction; more invasive options (intratympanic injections or surgery) are reserved for refractory, disabling cases. The Meniett device is designed to deliver low-pressure pulses to the middle ear via a tympanostomy tube with the intent of reducing vertigo symptoms, but long-term efficacy and hearing preservation remain uncertain.

Definitions and Device Description

Meniett™ device description and mechanism

Device nameMeniett™ transtympanic micropressure therapy (hand-held pressure pulse generator)

Delivery methodPressure pulses delivered to the middle ear via an implanted ventilation (tympanostomy) tube

Pulse characteristicsLow-frequency, low-amplitude pressure pulses transmitted through tubing and earplug

Usage regimenTypical treatment: 5 minutes, three times per day while symptoms persist (usually ≥2 weeks)

Patient administrationPatient can self-administer after prescription and tube placement

Regulatory statusFDA approved December 1999

Policy Revision History

2008-12-12effective_date

Policy became effective for the Georgia region.

2024-08-08last_revisionLatest

Document last revised and reviewed by Utilization Management Committee.